Review





Similar Products

95
InvivoGen recombinant human tnf α
(A) <t>TNF-α</t> neutralization by antibody variants. Dose-response curves for Golimumab, the inverted variant (C-C), and the ACT5 variant against 3 ng/mL TNF-α. The Y-axis shows the signal normalized to the TNF-α only control. Data are mean +/- SD from n=3 technical repeats. (B) FcRn-recycling efficiencies of Golimumab, the inverted variant, and the ACT5 variant. Data represent mean +/- SD (n=3). Statistical analysis by one-way ANOVA [F(2, 6) = 49.83, P = 0.0002] with Tukey’s multiple comparisons test. ns = not significant, ***: P < 0.001. (C) Serum concentration-time profiles and (D) CL of golimumab, the inverted, and the ACT5 variant determined in hFcRn Tg32 SDPK studies with IVIG coadministration. Data are mean +/- SD (n=3-4 mice per group). Data and statistical information are provided in Table S1.
Recombinant Human Tnf α, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+5/Recombinant+human+TNF-%CE%B1/bio_rxiv__64898__2026__11__02__763654-260-29-32
Average 95 stars, based on 1 article reviews
recombinant human tnf α - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
InvivoGen il 1β
Differentiated Caco-2/HT29-MTX-E12 co-cultures were treated with Alternaria mycotoxins as indicated for 2 h before the addition of <t>IL-1β</t> (0.5 ng/mL) for additional 18 h, and viability ( A ) and Barrier integrity; TEER ( B ) was measured. The data are expressed as mean + SD from four to six independent experiments. Significant difference (p< 0.05) compared to ctrl (0 µM) is indicated with an asterisk (*). One-way ANOVA with Dunnett’s post hoc test.
Il 1β, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+5/Recombinant+human+IL-1%CE%B2/bio_rxiv__64898__2026__10__30__761907-58-20-23
Average 95 stars, based on 1 article reviews
il 1β - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

93
MedChemExpress recombinant human fgf 5 protein

Recombinant Human Fgf 5 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+5/Animal-Free+FGF-5%2C+Human/pmc13694821-40-0-8
Average 93 stars, based on 1 article reviews
recombinant human fgf 5 protein - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
InvivoGen recombinant human il 2

Recombinant Human Il 2, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+5/Recombinant+human+IL-2/10__1038_slash_s41389___026___00665___7-71-16-19
Average 94 stars, based on 1 article reviews
recombinant human il 2 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Cusabio recombinant human solute carrier family 22 member 5

Recombinant Human Solute Carrier Family 22 Member 5, supplied by Cusabio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+5/SLC22A5/10__1021_slash_ehp__6c00076-110-17-35
Average 94 stars, based on 1 article reviews
recombinant human solute carrier family 22 member 5 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

95
InvivoGen tgfβ

Tgfβ, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+5/Recombinant+human+TGF-%CE%B21/10__1186_slash_s13046___026___03834___z-139-6-8
Average 95 stars, based on 1 article reviews
tgfβ - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
InvivoGen recombinant human il 1β
HU-308 attenuates <t>IL-1β-induced</t> interleukin expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of proinflammatory and anti-inflammatory interleukins were quantified. IL-1β stimulation significantly increased the expression of the pro-inflammatory cytokines IL1B, IL6, IL23A, IL33, IL11, IL1α, and IL24, and treatment with HU-308 attenuated the IL-1β-induced expression of these cytokines, indicating suppression of the inflammatory response ( A – F ). In contrast, IL10 exhibited reduced expression following IL-1β stimulation, and HU-308 treatment partially restored its expression, supporting a shift toward a less inflammatory phenotype following CB2 receptor activation ( G ). Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.
Recombinant Human Il 1β, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+5/Recombinant+human+IL-1%CE%B2/pmc13610315-406-0-6
Average 95 stars, based on 1 article reviews
recombinant human il 1β - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
InvivoGen recombinant human interferon gamma ifn γ
HU-308 attenuates <t>IL-1β-induced</t> interleukin expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of proinflammatory and anti-inflammatory interleukins were quantified. IL-1β stimulation significantly increased the expression of the pro-inflammatory cytokines IL1B, IL6, IL23A, IL33, IL11, IL1α, and IL24, and treatment with HU-308 attenuated the IL-1β-induced expression of these cytokines, indicating suppression of the inflammatory response ( A – F ). In contrast, IL10 exhibited reduced expression following IL-1β stimulation, and HU-308 treatment partially restored its expression, supporting a shift toward a less inflammatory phenotype following CB2 receptor activation ( G ). Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.
Recombinant Human Interferon Gamma Ifn γ, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+5/Recombinant+human+IFN-%CE%B3/pm42585817-87-7-14
Average 95 stars, based on 1 article reviews
recombinant human interferon gamma ifn γ - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

95
InvivoGen recombinant human tgf β1
HU-308 attenuates <t>IL-1β-induced</t> interleukin expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of proinflammatory and anti-inflammatory interleukins were quantified. IL-1β stimulation significantly increased the expression of the pro-inflammatory cytokines IL1B, IL6, IL23A, IL33, IL11, IL1α, and IL24, and treatment with HU-308 attenuated the IL-1β-induced expression of these cytokines, indicating suppression of the inflammatory response ( A – F ). In contrast, IL10 exhibited reduced expression following IL-1β stimulation, and HU-308 treatment partially restored its expression, supporting a shift toward a less inflammatory phenotype following CB2 receptor activation ( G ). Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.
Recombinant Human Tgf β1, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+5/Recombinant+human+TGF-%CE%B21/pmc13255678-151-5-9
Average 95 stars, based on 1 article reviews
recombinant human tgf β1 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

93
Beijing Solarbio Science recombinant human insulin
HU-308 attenuates <t>IL-1β-induced</t> interleukin expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of proinflammatory and anti-inflammatory interleukins were quantified. IL-1β stimulation significantly increased the expression of the pro-inflammatory cytokines IL1B, IL6, IL23A, IL33, IL11, IL1α, and IL24, and treatment with HU-308 attenuated the IL-1β-induced expression of these cytokines, indicating suppression of the inflammatory response ( A – F ). In contrast, IL10 exhibited reduced expression following IL-1β stimulation, and HU-308 treatment partially restored its expression, supporting a shift toward a less inflammatory phenotype following CB2 receptor activation ( G ). Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.
Recombinant Human Insulin, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+5/Recombinant+Human+Insulin-like+Growth+Factor-Binding+Protein+5%2FIGFBP5%2FIGFBP-5/10__1016_slash_j__cej__2026__180170-112-29-32
Average 93 stars, based on 1 article reviews
recombinant human insulin - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


(A) TNF-α neutralization by antibody variants. Dose-response curves for Golimumab, the inverted variant (C-C), and the ACT5 variant against 3 ng/mL TNF-α. The Y-axis shows the signal normalized to the TNF-α only control. Data are mean +/- SD from n=3 technical repeats. (B) FcRn-recycling efficiencies of Golimumab, the inverted variant, and the ACT5 variant. Data represent mean +/- SD (n=3). Statistical analysis by one-way ANOVA [F(2, 6) = 49.83, P = 0.0002] with Tukey’s multiple comparisons test. ns = not significant, ***: P < 0.001. (C) Serum concentration-time profiles and (D) CL of golimumab, the inverted, and the ACT5 variant determined in hFcRn Tg32 SDPK studies with IVIG coadministration. Data are mean +/- SD (n=3-4 mice per group). Data and statistical information are provided in Table S1.

Journal: bioRxiv

Article Title: Spatial architecture of complex antibody formats dictates pharmacokinetics via FcRn-recycling

doi: 10.64898/2026.11.02.763654

Figure Lengend Snippet: (A) TNF-α neutralization by antibody variants. Dose-response curves for Golimumab, the inverted variant (C-C), and the ACT5 variant against 3 ng/mL TNF-α. The Y-axis shows the signal normalized to the TNF-α only control. Data are mean +/- SD from n=3 technical repeats. (B) FcRn-recycling efficiencies of Golimumab, the inverted variant, and the ACT5 variant. Data represent mean +/- SD (n=3). Statistical analysis by one-way ANOVA [F(2, 6) = 49.83, P = 0.0002] with Tukey’s multiple comparisons test. ns = not significant, ***: P < 0.001. (C) Serum concentration-time profiles and (D) CL of golimumab, the inverted, and the ACT5 variant determined in hFcRn Tg32 SDPK studies with IVIG coadministration. Data are mean +/- SD (n=3-4 mice per group). Data and statistical information are provided in Table S1.

Article Snippet: For antibody inhibition assays, 20 ul of test antibody, serially diluted 1:3 in test medium, was added to the cells along with a constant final concentration of 3 ng/ml recombinant human TNF-α (InvivoGen).

Techniques: Neutralization, Variant Assay, Control, Analysis, Concentration Assay

Differentiated Caco-2/HT29-MTX-E12 co-cultures were treated with Alternaria mycotoxins as indicated for 2 h before the addition of IL-1β (0.5 ng/mL) for additional 18 h, and viability ( A ) and Barrier integrity; TEER ( B ) was measured. The data are expressed as mean + SD from four to six independent experiments. Significant difference (p< 0.05) compared to ctrl (0 µM) is indicated with an asterisk (*). One-way ANOVA with Dunnett’s post hoc test.

Journal: bioRxiv

Article Title: From cellular stress to cytokine modulation: An in vitro study of intestinal effects of major Alternaria mycotoxins

doi: 10.64898/2026.10.30.761907

Figure Lengend Snippet: Differentiated Caco-2/HT29-MTX-E12 co-cultures were treated with Alternaria mycotoxins as indicated for 2 h before the addition of IL-1β (0.5 ng/mL) for additional 18 h, and viability ( A ) and Barrier integrity; TEER ( B ) was measured. The data are expressed as mean + SD from four to six independent experiments. Significant difference (p< 0.05) compared to ctrl (0 µM) is indicated with an asterisk (*). One-way ANOVA with Dunnett’s post hoc test.

Article Snippet: For exposure to a combination of toxin and IL-1β, the cells were first incubated with toxins for 2 h then IL-1β (0.5 ng/mL, Invivogen, CA, USA) was added apically.

Techniques: Co-Cultures

Differentiated Caco-2/HT29-MTX-E12 co-cultures were treated with Alternaria mycotoxins as indicated for 2 h before the addition of IL-1β (0.5 ng/mL) for additional 18 h, and IL-8 secretion was measured. The data are expressed as mean + SD from four to six independent experiments. Significant difference (p< 0.05) compared to ctrl (0 µM) is indicated with an asterisk (*). One-way ANOVA with Dunnett’s post hoc test.

Journal: bioRxiv

Article Title: From cellular stress to cytokine modulation: An in vitro study of intestinal effects of major Alternaria mycotoxins

doi: 10.64898/2026.10.30.761907

Figure Lengend Snippet: Differentiated Caco-2/HT29-MTX-E12 co-cultures were treated with Alternaria mycotoxins as indicated for 2 h before the addition of IL-1β (0.5 ng/mL) for additional 18 h, and IL-8 secretion was measured. The data are expressed as mean + SD from four to six independent experiments. Significant difference (p< 0.05) compared to ctrl (0 µM) is indicated with an asterisk (*). One-way ANOVA with Dunnett’s post hoc test.

Article Snippet: For exposure to a combination of toxin and IL-1β, the cells were first incubated with toxins for 2 h then IL-1β (0.5 ng/mL, Invivogen, CA, USA) was added apically.

Techniques: Co-Cultures

The EpiIntestinal™ FT tissues were treated with AOH, AME, and TeA for 2 h before the addition of IL-1β (0.5 ng/mL) for an additional 18 h, and viability / metabolic activity ( A ) and barrier integrity ( B ) were measured. The data are expressed as mean + SD from two independent incubations. Significant difference (p< 0.05) compared to IL-1β is indicated with an asterisk (*). One-way ANOVA with Dunnett’s post hoc test.

Journal: bioRxiv

Article Title: From cellular stress to cytokine modulation: An in vitro study of intestinal effects of major Alternaria mycotoxins

doi: 10.64898/2026.10.30.761907

Figure Lengend Snippet: The EpiIntestinal™ FT tissues were treated with AOH, AME, and TeA for 2 h before the addition of IL-1β (0.5 ng/mL) for an additional 18 h, and viability / metabolic activity ( A ) and barrier integrity ( B ) were measured. The data are expressed as mean + SD from two independent incubations. Significant difference (p< 0.05) compared to IL-1β is indicated with an asterisk (*). One-way ANOVA with Dunnett’s post hoc test.

Article Snippet: For exposure to a combination of toxin and IL-1β, the cells were first incubated with toxins for 2 h then IL-1β (0.5 ng/mL, Invivogen, CA, USA) was added apically.

Techniques: Activity Assay

The EpiIntestinal ™ FT tissues were treated with AOH, AME, and TeA for 2 h before the addition of IL-1β (0.5 ng/mL) for an additional 18 h. IL-8 ( A ) and IL-6 ( B ) cytokine secretion was measured by ELISA. The data are expressed as mean + SD from two independent incubations, measured in triplicate. Significant difference (p< 0.05) compared to IL-1β is indicated with an asterisk (*). One-way ANOVA with Dunnett’s post hoc test.

Journal: bioRxiv

Article Title: From cellular stress to cytokine modulation: An in vitro study of intestinal effects of major Alternaria mycotoxins

doi: 10.64898/2026.10.30.761907

Figure Lengend Snippet: The EpiIntestinal ™ FT tissues were treated with AOH, AME, and TeA for 2 h before the addition of IL-1β (0.5 ng/mL) for an additional 18 h. IL-8 ( A ) and IL-6 ( B ) cytokine secretion was measured by ELISA. The data are expressed as mean + SD from two independent incubations, measured in triplicate. Significant difference (p< 0.05) compared to IL-1β is indicated with an asterisk (*). One-way ANOVA with Dunnett’s post hoc test.

Article Snippet: For exposure to a combination of toxin and IL-1β, the cells were first incubated with toxins for 2 h then IL-1β (0.5 ng/mL, Invivogen, CA, USA) was added apically.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: iScience

Article Title: Serum Olink proteomics-based exploration of novel predictive biomarkers for necrotizing enterocolitis

doi: 10.1016/j.isci.2026.117617

Figure Lengend Snippet:

Article Snippet: Recombinant Human FGF-5 protein (Animal-Free, C-His tag) , MedChemExpress (MCE) , Cat# HY-P700067AF; Lot: 268797; Species: Human; Expressed in E. coli; MW: 28.46 kDa; Purity ≥95%.

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay

HU-308 attenuates IL-1β-induced interleukin expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of proinflammatory and anti-inflammatory interleukins were quantified. IL-1β stimulation significantly increased the expression of the pro-inflammatory cytokines IL1B, IL6, IL23A, IL33, IL11, IL1α, and IL24, and treatment with HU-308 attenuated the IL-1β-induced expression of these cytokines, indicating suppression of the inflammatory response ( A – F ). In contrast, IL10 exhibited reduced expression following IL-1β stimulation, and HU-308 treatment partially restored its expression, supporting a shift toward a less inflammatory phenotype following CB2 receptor activation ( G ). Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.

Journal: Pharmaceuticals

Article Title: CB2 Receptor Activation Attenuates IL-1β-Induced Inflammatory Transcriptomic Networks in Human Gingival Fibroblasts

doi: 10.3390/ph19091406

Figure Lengend Snippet: HU-308 attenuates IL-1β-induced interleukin expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of proinflammatory and anti-inflammatory interleukins were quantified. IL-1β stimulation significantly increased the expression of the pro-inflammatory cytokines IL1B, IL6, IL23A, IL33, IL11, IL1α, and IL24, and treatment with HU-308 attenuated the IL-1β-induced expression of these cytokines, indicating suppression of the inflammatory response ( A – F ). In contrast, IL10 exhibited reduced expression following IL-1β stimulation, and HU-308 treatment partially restored its expression, supporting a shift toward a less inflammatory phenotype following CB2 receptor activation ( G ). Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.

Article Snippet: Recombinant human IL-1β was obtained from (InvivoGen, San Diego, CA, USA), reconstituted in water according to the manufacturer’s instructions, and used at a final concentration of 10 ng/mL.

Techniques: Expressing, Control, Activation Assay, Comparison

HU-308 modulates IL-1β-induced chemokine expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of inflammatory chemokines were quantified. IL-1β stimulation significantly increased the expression of CXCL5, CXCL8, CXCL16, CCL20, and CCL28, consistent with activation of chemokine-mediated inflammatory signaling ( A – E ). Treatment with HU-308 attenuated the IL-1β-induced expression of these chemokines, indicating suppression of inflammatory chemokine responses and reduced potential for immune-cell recruitment ( A – E ). Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.

Journal: Pharmaceuticals

Article Title: CB2 Receptor Activation Attenuates IL-1β-Induced Inflammatory Transcriptomic Networks in Human Gingival Fibroblasts

doi: 10.3390/ph19091406

Figure Lengend Snippet: HU-308 modulates IL-1β-induced chemokine expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of inflammatory chemokines were quantified. IL-1β stimulation significantly increased the expression of CXCL5, CXCL8, CXCL16, CCL20, and CCL28, consistent with activation of chemokine-mediated inflammatory signaling ( A – E ). Treatment with HU-308 attenuated the IL-1β-induced expression of these chemokines, indicating suppression of inflammatory chemokine responses and reduced potential for immune-cell recruitment ( A – E ). Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.

Article Snippet: Recombinant human IL-1β was obtained from (InvivoGen, San Diego, CA, USA), reconstituted in water according to the manufacturer’s instructions, and used at a final concentration of 10 ng/mL.

Techniques: Expressing, Control, Activation Assay, Immune Cell, Comparison

HU-308 attenuates IL-1β-induced matrix metalloproteinase expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of MMP1, MMP3, and MMP10 were quantified. IL-1β stimulation significantly increased the expression of all three matrix metalloproteinases, consistent with enhanced extracellular matrix degradation and tissue remodeling associated with periodontal inflammation ( A – C ). Treatment with HU-308 significantly attenuated the IL-1β-induced expression of MMP1, MMP3, and MMP10, suggesting that CB2 receptor modulation suppresses matrix-degrading pathways and may contribute to the preservation of periodontal tissue integrity ( A – C ). Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.

Journal: Pharmaceuticals

Article Title: CB2 Receptor Activation Attenuates IL-1β-Induced Inflammatory Transcriptomic Networks in Human Gingival Fibroblasts

doi: 10.3390/ph19091406

Figure Lengend Snippet: HU-308 attenuates IL-1β-induced matrix metalloproteinase expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of MMP1, MMP3, and MMP10 were quantified. IL-1β stimulation significantly increased the expression of all three matrix metalloproteinases, consistent with enhanced extracellular matrix degradation and tissue remodeling associated with periodontal inflammation ( A – C ). Treatment with HU-308 significantly attenuated the IL-1β-induced expression of MMP1, MMP3, and MMP10, suggesting that CB2 receptor modulation suppresses matrix-degrading pathways and may contribute to the preservation of periodontal tissue integrity ( A – C ). Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.

Article Snippet: Recombinant human IL-1β was obtained from (InvivoGen, San Diego, CA, USA), reconstituted in water according to the manufacturer’s instructions, and used at a final concentration of 10 ng/mL.

Techniques: Expressing, Control, Tissue, Preserving, Comparison

HU-308 partially restores IL-1β-induced alterations in collagen gene expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of COL1A1, COL3A1, COL11A1, and COL12A1 were quantified. IL-1β stimulation significantly reduced the expression of collagen-associated genes, consistent with impaired extracellular matrix synthesis and tissue remodeling during periodontal inflammation ( A – D ). Treatment with HU-308 partially restored the expression of these collagen transcripts toward control levels, suggesting that CB2 receptor activation may preserve extracellular matrix homeostasis and limit IL-1β-induced connective tissue damage ( A – D ). Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01 and *** p < 0.001 was considered statistically significant.

Journal: Pharmaceuticals

Article Title: CB2 Receptor Activation Attenuates IL-1β-Induced Inflammatory Transcriptomic Networks in Human Gingival Fibroblasts

doi: 10.3390/ph19091406

Figure Lengend Snippet: HU-308 partially restores IL-1β-induced alterations in collagen gene expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of COL1A1, COL3A1, COL11A1, and COL12A1 were quantified. IL-1β stimulation significantly reduced the expression of collagen-associated genes, consistent with impaired extracellular matrix synthesis and tissue remodeling during periodontal inflammation ( A – D ). Treatment with HU-308 partially restored the expression of these collagen transcripts toward control levels, suggesting that CB2 receptor activation may preserve extracellular matrix homeostasis and limit IL-1β-induced connective tissue damage ( A – D ). Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01 and *** p < 0.001 was considered statistically significant.

Article Snippet: Recombinant human IL-1β was obtained from (InvivoGen, San Diego, CA, USA), reconstituted in water according to the manufacturer’s instructions, and used at a final concentration of 10 ng/mL.

Techniques: Gene Expression, Control, Expressing, Tissue, Activation Assay, Comparison

HU-308 modulates IL-1β-induced nitric oxide and oxidative stress-related gene expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of NOS3, PRKG1 and PDE5A were quantified. IL-1β stimulation significantly altered the expression of genes involved in nitric oxide signaling, reflecting activation of redox-associated inflammatory pathways ( A – C ). Treatment with HU-308 modulated the IL-1β-induced expression of these genes, partially restoring their expression toward control levels and suggesting that CB2 receptor activation attenuates redox imbalance and nitric oxide signaling dysregulation associated with inflammatory activation ( A – C ). Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.

Journal: Pharmaceuticals

Article Title: CB2 Receptor Activation Attenuates IL-1β-Induced Inflammatory Transcriptomic Networks in Human Gingival Fibroblasts

doi: 10.3390/ph19091406

Figure Lengend Snippet: HU-308 modulates IL-1β-induced nitric oxide and oxidative stress-related gene expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of NOS3, PRKG1 and PDE5A were quantified. IL-1β stimulation significantly altered the expression of genes involved in nitric oxide signaling, reflecting activation of redox-associated inflammatory pathways ( A – C ). Treatment with HU-308 modulated the IL-1β-induced expression of these genes, partially restoring their expression toward control levels and suggesting that CB2 receptor activation attenuates redox imbalance and nitric oxide signaling dysregulation associated with inflammatory activation ( A – C ). Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.

Article Snippet: Recombinant human IL-1β was obtained from (InvivoGen, San Diego, CA, USA), reconstituted in water according to the manufacturer’s instructions, and used at a final concentration of 10 ng/mL.

Techniques: Gene Expression, Control, Expressing, Activation Assay, Comparison

HU-308 modulates IL-1β-associated changes in solute carrier transporter transcript expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of SLC2A1, SLC2A3, SLC2A5, SLC5A13, and SLC2A14 were quantified. IL-1β stimulation significantly altered the expression of SLC2A1, SLC2A3, SLC2A5, SLC2A13, and SLC2A14, and HU-308 treatment significantly modified several of these IL-1β-associated transcriptional responses ( A – E ). These findings demonstrate changes in transporter-associated transcript abundance but do not establish corresponding alterations in substrate uptake, glucose utilization, glycolytic activity, or cellular metabolic flux. Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.

Journal: Pharmaceuticals

Article Title: CB2 Receptor Activation Attenuates IL-1β-Induced Inflammatory Transcriptomic Networks in Human Gingival Fibroblasts

doi: 10.3390/ph19091406

Figure Lengend Snippet: HU-308 modulates IL-1β-associated changes in solute carrier transporter transcript expression in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of SLC2A1, SLC2A3, SLC2A5, SLC5A13, and SLC2A14 were quantified. IL-1β stimulation significantly altered the expression of SLC2A1, SLC2A3, SLC2A5, SLC2A13, and SLC2A14, and HU-308 treatment significantly modified several of these IL-1β-associated transcriptional responses ( A – E ). These findings demonstrate changes in transporter-associated transcript abundance but do not establish corresponding alterations in substrate uptake, glucose utilization, glycolytic activity, or cellular metabolic flux. Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.

Article Snippet: Recombinant human IL-1β was obtained from (InvivoGen, San Diego, CA, USA), reconstituted in water according to the manufacturer’s instructions, and used at a final concentration of 10 ng/mL.

Techniques: Expressing, Control, Modification, Activity Assay, Comparison

GPCR-related transcript modulation by IL-1β and HU-308 treatment in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of GPR160, GPR180, GPR157, GPR61, GPR173, GPR155, GPR107, GPR75, GPR78, and GPR4 were quantified. IL-1β stimulation significantly altered the expression of multiple GPCR-related genes, including increased expression of GPR160, GPR180, GPR157, GPR61, GPR173, GPR155, GPR107, and GPR75, while reducing the expression of GPR78 and GPR4, indicating inflammatory remodeling of GPCR-associated signaling pathways in human gingival fibroblasts ( A – J ). Treatment with HU-308 modified several IL-1β-associated changes in GPCR-related transcript expression ( A – J ). These changes represent transcriptional associations and should not be interpreted as evidence of altered receptor activity or direct functional cross-talk with CB2. Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.

Journal: Pharmaceuticals

Article Title: CB2 Receptor Activation Attenuates IL-1β-Induced Inflammatory Transcriptomic Networks in Human Gingival Fibroblasts

doi: 10.3390/ph19091406

Figure Lengend Snippet: GPCR-related transcript modulation by IL-1β and HU-308 treatment in human gingival fibroblasts. Human gingival fibroblasts (HGFs) were divided into three experimental groups: untreated Control (black bars), IL-1β (10 ng/mL)-stimulated cells (red bars), and cells treated with IL-1β followed by the selective CB2 receptor agonist HU-308 (10 μM; blue bars). Twenty-four hours after IL-1β stimulation, transcript levels of GPR160, GPR180, GPR157, GPR61, GPR173, GPR155, GPR107, GPR75, GPR78, and GPR4 were quantified. IL-1β stimulation significantly altered the expression of multiple GPCR-related genes, including increased expression of GPR160, GPR180, GPR157, GPR61, GPR173, GPR155, GPR107, and GPR75, while reducing the expression of GPR78 and GPR4, indicating inflammatory remodeling of GPCR-associated signaling pathways in human gingival fibroblasts ( A – J ). Treatment with HU-308 modified several IL-1β-associated changes in GPCR-related transcript expression ( A – J ). These changes represent transcriptional associations and should not be interpreted as evidence of altered receptor activity or direct functional cross-talk with CB2. Data are presented as mean ± SEM from three independent biological replicates ( n = 3 per group). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple-comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 was considered statistically significant.

Article Snippet: Recombinant human IL-1β was obtained from (InvivoGen, San Diego, CA, USA), reconstituted in water according to the manufacturer’s instructions, and used at a final concentration of 10 ng/mL.

Techniques: Control, Expressing, Protein-Protein interactions, Modification, Activity Assay, Functional Assay, Comparison

Schematic summary of the coordinated anti-inflammatory effects of CB2 receptor activation in IL-1β-stimulated human gingival fibroblasts. IL-1β stimulation establishes a pro-inflammatory transcriptional landscape characterized by coordinated upregulation of inflammatory cytokines, chemokines, matrix metalloproteinases (MMPs), glucose transporter (SLC2/GLUT) genes, and multiple G protein-coupled receptor (GPCR)-related transcripts, together with suppression of collagen-associated genes and nitric oxide (NO)/cGMP signaling components. Collectively, these changes promote inflammatory amplification, extracellular matrix degradation, metabolic reprogramming, impaired tissue repair, and disruption of periodontal homeostasis ( left panel ). Pharmacological modulation of the cannabinoid receptor type 2 (CB2) with the selective agonist HU-308 shifts this inflammatory landscape toward a more homeostatic phenotype (center panel). HU-308 broadly attenuates IL-1β-induced inflammatory responses by reducing the expression of pro-inflammatory cytokines, chemokines, MMPs, glucose transporter-related genes, and several GPR-associated transcripts, while restoring collagen gene expression, NO/cGMP signaling, and selected receptor-associated pathways ( right panel ). Upward and downward arrows beneath each biological domain summarize the direction of transcript changes for individual genes following IL-1β stimulation (red arrows) and subsequent HU-308 treatment (blue arrows). Overall, the integrated pathway analysis demonstrates that CB2 modulation functions as an upstream regulator of multiple interconnected biological networks, including inflammatory signaling, extracellular matrix remodeling, redox homeostasis, metabolic adaptation, and GPR-associated signaling, rather than acting on a single molecular pathway, thereby supporting a systems-level mechanism through which CB2 modulation may preserve periodontal tissue homeostasis during inflammation. This figure represents a conceptual summary of selected transcriptional patterns and does not constitute a statistically derived gene-network, pathway-enrichment, or genome-wide differential-expression analysis.

Journal: Pharmaceuticals

Article Title: CB2 Receptor Activation Attenuates IL-1β-Induced Inflammatory Transcriptomic Networks in Human Gingival Fibroblasts

doi: 10.3390/ph19091406

Figure Lengend Snippet: Schematic summary of the coordinated anti-inflammatory effects of CB2 receptor activation in IL-1β-stimulated human gingival fibroblasts. IL-1β stimulation establishes a pro-inflammatory transcriptional landscape characterized by coordinated upregulation of inflammatory cytokines, chemokines, matrix metalloproteinases (MMPs), glucose transporter (SLC2/GLUT) genes, and multiple G protein-coupled receptor (GPCR)-related transcripts, together with suppression of collagen-associated genes and nitric oxide (NO)/cGMP signaling components. Collectively, these changes promote inflammatory amplification, extracellular matrix degradation, metabolic reprogramming, impaired tissue repair, and disruption of periodontal homeostasis ( left panel ). Pharmacological modulation of the cannabinoid receptor type 2 (CB2) with the selective agonist HU-308 shifts this inflammatory landscape toward a more homeostatic phenotype (center panel). HU-308 broadly attenuates IL-1β-induced inflammatory responses by reducing the expression of pro-inflammatory cytokines, chemokines, MMPs, glucose transporter-related genes, and several GPR-associated transcripts, while restoring collagen gene expression, NO/cGMP signaling, and selected receptor-associated pathways ( right panel ). Upward and downward arrows beneath each biological domain summarize the direction of transcript changes for individual genes following IL-1β stimulation (red arrows) and subsequent HU-308 treatment (blue arrows). Overall, the integrated pathway analysis demonstrates that CB2 modulation functions as an upstream regulator of multiple interconnected biological networks, including inflammatory signaling, extracellular matrix remodeling, redox homeostasis, metabolic adaptation, and GPR-associated signaling, rather than acting on a single molecular pathway, thereby supporting a systems-level mechanism through which CB2 modulation may preserve periodontal tissue homeostasis during inflammation. This figure represents a conceptual summary of selected transcriptional patterns and does not constitute a statistically derived gene-network, pathway-enrichment, or genome-wide differential-expression analysis.

Article Snippet: Recombinant human IL-1β was obtained from (InvivoGen, San Diego, CA, USA), reconstituted in water according to the manufacturer’s instructions, and used at a final concentration of 10 ng/mL.

Techniques: Activation Assay, Amplification, Tissue, Disruption, Expressing, Gene Expression, Analysis, Derivative Assay, Genome Wide, Quantitative Proteomics